VJHemOnc Podcast iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
May 18, 2023
Experts discuss the challenges and future outlooks of CAR-T therapy in acute lymphoblastic leukemia (ALL), including the potential effectiveness of Auto3, the need for randomized studies, optimizing dual targeting CAR-T therapy, and unifying data from different delivery methods and manufacturing techniques. They also explore reverse translation and the importance of target selection, car constructs, T cell attributes, and investigating the tumor microenvironment in optimizing patients for CAR T cell immunotherapy. Factors affecting selective expansion of CAR-T therapy in ALL patients, the influence of prior CD19-directed therapy, and the need for better products and a preclinical platform for measuring T cell function are also discussed. Lastly, they explore the dilemma of choosing between approved CAR-T products and experimental ones as frontline therapy, emphasize the importance of informed consent, and highlight the potential benefits of dual targeting in CAR-T therapy for ALL treatment.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Challenges and Future of CAR-T Therapy in Acute Lymphoblastic Leukemia
01:51 • 4min
Reverse Translation and Optimizing CAR T Cell Immunotherapy
05:47 • 3min
Challenges and Factors Affecting CAR-T Therapy Expansion in ALL Patients
08:18 • 2min
Challenges and considerations in using CAR-T therapy for ALL treatment
10:34 • 4min